CRISPR技术在生物学与医学中的研究进展

doi:10.13560/j.cnki.biotech.bull.1985.2019-0147

生物技术通报 ›› 2020, Vol. 36 ›› Issue (3): 38-44.doi: 10.13560/j.cnki.biotech.bull.1985.2019-0147

• 基因编辑专题（专题主编谷峰研究员） • 上一篇下一篇

CRISPR技术在生物学与医学中的研究进展

杨悦^{1, 2}, 高郡茹³, 杨柳^{1, 2}

1. 广西师范大学生物医学研究中心,桂林 541004;
2. 广西师范大学干细胞与医药生物技术重点实验室,桂林 541004;
3. 广西师范大学生命科学学院,桂林 541004

收稿日期:2019-02-25 出版日期:2020-03-26 发布日期:2020-03-17
作者简介:杨悦,女,硕士,研究方向：重大疾病分子机理;E-mail：changlanxue@hotmail.com
基金资助:
国家自然科学基金项目（31560319）,广西高校大学生创新训练项目（201810602063）

Research Progress on CRISPR Technology in Biology and Medical Science

YANG Yue^{1, 2}, GAO Jun-ru³, YANG Liu^{1, 2}

1. Research Center for Biomedical Sciences,Guangxi Normal University,Guilin 541004;
2. Guangxi Universities Key Laboratory of Stem cell and Biopharmaceutical Technology,Guilin 541004;
3.College of Sciences,Guangxi Normal University,Guilin 541004

Received:2019-02-25 Published:2020-03-26 Online:2020-03-17

摘要/Abstract

摘要： 作为一项新兴技术,CRISPR近年来发展迅速,其在疾病检测、模式生物构建、基因治疗领域的研究硕果累累。由于CRISPR技术原理简单、操作简易,并可与多种技术结合等优点,使之在医药、农业、环境等领域的应用具有巨大潜力。此外,除了经典的CRISPR/Cas9系统,科学家还发现了多种其他类型的CRISPR/Cas系统。同时,基于Cas9蛋白开发的单碱基编辑器（BE）和可对RNA进行编辑的CRISPR/Cas13a系统也使CRISPR的应用范围得到了极大地扩展,将对CRISPR技术的最新进展及其在生物学、医学等领域的应用进行综述。

关键词: CRIPSR/Cas9, 单碱基编辑, RNA编辑, 基因治疗

Abstract: As an emerging technology,CRISPR has been developing rapidly in recent years,and there are great research achievements in disease detection,as well as in the construction of model organisms and gene therapy field. As its simple principle,easy to operate and it can be combined with a variety of technologies,CRISPR technology has great potential in medicine,agriculture,environment and other fields. In addition to the classic CRISPR/cas9 system,scientists have discovered various other types CRISPR/Cas system. Meanwhile,the single base editor（BE）based on Cas9 protein and the CRISPR/Cas13a system that can edit RNA also greatly expand the application range of CRISPR. This article will review the latest development of CRISPR technology and its application in biology,medicine and other fields.

Key words: CRISPR/Cas9, single base editor, RNA editing, gene therapy

杨悦, 高郡茹, 杨柳. CRISPR技术在生物学与医学中的研究进展[J]. 生物技术通报, 2020, 36(3): 38-44.

YANG Yue, GAO Jun-ru, YANG Liu. Research Progress on CRISPR Technology in Biology and Medical Science[J]. Biotechnology Bulletin, 2020, 36(3): 38-44.

参考文献

[1] Ran FA, Hsu PD, Wright J, et al.Genome engineering using the CRISPR-Cas9 system[J]. Nature Protocols, 2013, 8(11):2281-2308.
[2] Knott GJ, Doudna JA.CRISPR-Cas guides the future of genetic engineering[J]. Science, 2018, 361(6405):866.
[3] Kieper SN, Almendros C, Behler J, et al.Cas4 facilitates PAM-compatible spacer selection during CRISPR adaptation[J]. Cell Reports, 2018, 22(13):3377-3384.
[4] Hsu PD, Scott DA, Weinstein JA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases[J]. Nat Biotechnol, 2013, 31(9):827-832.
[5] Jinek M, East A, Cheng A, et al.RNA-programmed genome editing in human cells[J]. eLife, 2013, 2:e00471.
[6] Hu JH, Miller SM, Geurts MH, et al.Evolved Cas9 variants with broad PAM compatibility and high DNA specificity[J]. Nature, 2018, 556(7699):57-63.
[7] Teng F, Cui T, Feng G, et al.Repurposing CRISPR-Cas12b for mammalian genome engineering[J]. Cell Discovery, 2018, 4:63.
[8] Harrington LB, Burstein D, Chen JS, et al.Programmed DNA destruction by miniature CRISPR-Cas14 enzymes[J]. Science, 2018, 362(6416):839.
[9] Liu JJ, Orlova N, Oakes BL, et al.CasX enzymes comprise a distinct family of RNA-guided genome editors[J]. Nature, 2019, 556:218-223.
[10] Komor AC, Kim YB, Packer MS, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage[J]. Nature, 2016, 533(7603):420-424.
[11] Kim YB, Komor AC, Levy JM, et al.Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions[J]. Nat Biotechnol, 2017, 35(4):371-376.
[12] Komor AC, Zhao KT, Packer MS, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity[J]. Science Advances, 2017, 3(8):eaao4774.
[13] Li X, Wang Y, Liu Y, et al.Base editing with a Cpf1-cytidine deaminase fusion[J]. Nat Biotechnol, 2018, 36:324.
[14] Gaudelli NM, Komor AC, Rees HA, et al.Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage[J]. Nature, 2017, 551(7681):464-471.
[15] East-Seletsky A, O’connell MR, Knight SC, et al.Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection[J]. Nature, 2016, 538(7624):270-273.
[16] Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al.RNA targeting with CRISPR-Cas13[J]. Nature, 2017, 550(7675):280-284.
[17] Konermann S, Lotfy P, Brideau NJ, et al.Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors[J]. Cell, 2018, 173(3):665-676.
[18] Scotti MM, Swanson MS.RNA mis-splicing in disease[J]. Nature Reviews Genetics, 2016, 17(1):19-32.
[19] 王影, 李相敢, 邱丽娟. CRISPR/Cas9基因组定点编辑中脱靶现象的研究进展[J]. 植物学报, 2018, (4):528-541.
[20] Ihry RJ, Worringer KA, Salick MR, et al.p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells[J]. Nature Medicine, 2018, 24(7):939-946.
[21] Haapaniemi E, Botla S, Persson J, et al.CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response[J]. Nature Medicine, 2018, 24(7):927-930.
[22] Cullot G, Boutin J, Toutain J, et al.CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations[J]. Nature Communications, 2019, 10(1):1136-1136.
[23] Kosicki M, Tomberg K, Bradley A.Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements[J]. Nat Biotechnol, 2018, 36:765.
[24] Kim D, Bae S, Park J, et al.Digenome-seq:genome-wide profiling of CRISPR-Cas9 off-target effects in human cells[J]. Nature Methods, 2015, 12:237-243.
[25] Jin S, Zong Y, Gao Q, et al.Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice[J]. Science, 2019, 364(6437):292-295.
[26] Rossidis AC, Stratigis JD, Chadwick AC, et al.In utero CRISPR-mediated therapeutic editing of metabolic genes[J]. Nature Medicine, 2018, 24(10):1513-1518.
[27] Villiger L, Grisch-Chan HM, Lindsay H, et al.Treatment of a metabolic liver disease by in vivo genome base editing in adult mice[J]. Nature Medicine, 2018, 24(10):1519-1525.
[28] Zuo E, Sun Y, Wei W, et al.Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos[J]. Science, 2019:eaav9973.
[29] Liang P, Xie X, Zhi S, et al.Genome-wide profiling of adenine base editor specificity by EndoV-seq[J]. Nature Communications, 2019, 10(1):67-67.
[30] Kim D, Kim DE, Lee G, et al.Genome-wide target specificity of CRISPR RNA-guided adenine base editors[J]. Nat Biotechnol, 2019.
[31] Kim K, Ryu SM, Kim ST, et al.Highly efficient RNA-guided base editing in mouse embryos[J]. Nat Biotechnol, 2017, 35:435.
[32] Yan S, Tu Z, Liu Z, et al. A huntingtin knockin pig model recapitu-lates features of selective neurodegeneration in huntington’s dise-ase[J]. Cell, 2018, 173(4):989-1002. e13.
[33] Yang W, Liu Y, Tu Z, et al.CRISPR/Cas9-mediated PINK1 dele-tion leads to neurodegeneration in rhesus monkeys[J]. Cell Research, 2019, 29(4):334-336.
[34] Sheth RU, Yim SS, Wu FL, et al.Multiplex recording of cellular events over time on CRISPR biological tape[J]. Science, 2017, 358(6369):1457-1461.
[35] Tang W, Liu DR. Rewritable multi-event analog recording in bacterial and mammalian cells[J]. Science, 2018, 360(6385):eaap8992.
[36] Spanjaard B, Hu B, Mitic N, et al.Simultaneous lineage tracing and cell-type identification using CRISPR-Cas9-induced genetic scars[J]. Nat Biotechnol, 2018, 36(5):469-473.
[37] Mikheikin A, Olsen A, Leslie K, et al.DNA nanomapping using CRISPR-Cas9 as a programmable nanoparticle[J]. Nature Communications, 2017, 8(1):1665.
[38] Rogers ZN, Mcfarland CD, Winters IP, et al.Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice[J]. Nature Genetics, 2018, 50(4):483-486.
[39] Eyquem J, Mansilla-Soto J, Giavridis T, et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J]. Nature, 2017, 543(7643):113-117.
[40] Beyret E, Liao HK, Yamamoto M, et al.Single-dose CRISPR-Cas9 therapy extends lifespan of mice with Hutchinson-Gilford progeria syndrome[J]. Nature Medicine, 2019, 25(3):419-422.
[41] Nelson CE, Wu Y, Gemberling MP, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy[J]. Nature Medicine, 2019, 25(3)427-432.
[42] Yin L, Hu S, Mei S, et al.CRISPR/Cas9 inhibits multiple steps of HIV-1 infection[J]. Hum Gene Ther, 2018, 29(11):1264-1276.

CRISPR技术在生物学与医学中的研究进展

Research Progress on CRISPR Technology in Biology and Medical Science

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱琳, 鲜凤君, 张倩楠, 胡骏. RNA编辑的研究进展[J]. 生物技术通报, 2022, 38(1): 1-14.
[2]	陈敏洁, 唐桂月, 洪香娜, 郝沛, 江静, 李轩. 基于CRISPR-Cas13家族的RNA编辑系统及其最新进展[J]. 生物技术通报, 2020, 36(3): 1-8.
[3]	李裕华, 任永康, 赵兴华, 刘江, 韩斌, 王长彪, 唐朝晖. 禾本科主要农作物叶绿体基因组研究进展[J]. 生物技术通报, 2020, 36(11): 112-121.
[4]	张文君, 吴梦婷, 吕春艳, 王晴, 陈泳霖. 介孔二氧化硅在药物递送系统及其体内外研究进展[J]. 生物技术通报, 2019, 35(12): 159-168.
[5]	梁丽琴,阎婧,张鑫,郝泽婷,段江燕. CRISPR技术的发展及应用研究进展[J]. 生物技术通报, 2018, 34(5): 9-16.
[6]	李泰明, 许麒麟, 潘俊杰, 刘晓玫, 张春. AAV-ITR基因表达微载体在小鼠体内表达[J]. 生物技术通报, 2016, 32(5): 246-254.
[7]	郭兴荣,王小莉,袁雅红,涂汉军. PTEN mRNA编辑的间充质干细胞对神经胶质瘤U251细胞杀伤作用研究[J]. 生物技术通报, 2016, 32(4): 234-241.
[8]	殷子斐, 王丽娜, 王园, 凌晨. 提高重组型腺相关病毒转导效率的研究现状[J]. 生物技术通报, 2015, 31(9): 49-59.
[9]	占申标,唐明青,甘娜,曹苑青,李招发. rAAV规模化包装系统的研究进展[J]. 生物技术通报, 2015, 31(12): 63-69.
[10]	周培杰,高维强,方煜翔. 一种嵌合型调控元件在肿瘤靶向基因治疗中的应用[J]. 生物技术通报, 2015, 31(10): 255-262.
[11]	万平. 陆生植物线粒体RNA编辑进化分析[J]. 生物技术通报, 2013, 0(6): 99-103.
[12]	万平. 陆生植物叶绿体RNA编辑进化分析[J]. 生物技术通报, 2013, 0(5): 73-76.
[13]	何峙峤, 毋丽娜, 朱晓辉, 马腾, 邱晓彦. Ig启动子有效启动肿瘤抑制基因的表达研究[J]. 生物技术通报, 2013, 0(11): 136-141.
[14]	尹帮旗;连文昌;惠二京;李招发;. AAV在基因治疗中的靶向修饰研究进展[J]. , 2012, 0(02): 33-40.
[15]	代鹏;沈辉;马军武;刘光远;. RNA编辑功能和RNA干扰[J]. , 2011, 0(05): 21-25.